

Resource Summary Report

Generated by [kravitz2](#) on Sep 5, 2026

[sigma-tau](#)

RRID:SCR_000488

Type: Tool

Proper Citation

sigma-tau (RRID:SCR_000488)

Resource Information

URL: <http://www.sigma-tau.it/eng/>

Proper Citation: sigma-tau (RRID:SCR_000488)

Description: Italian pharmaceutical company involved in research, manufacture and marketing of drugs. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs.

Abbreviations: sigma-tau

Synonyms: , sigma-tau s.p.a., Leadiant Biosciences

Resource Type: commercial organization

Keywords: pharmaceutical, drug

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: sigma-tau

Resource ID: SCR_000488

Alternate IDs: nlx_158258

Alternate URLs: <https://leadiant.com/>

Record Creation Time: 20220129T080201+0000

Record Last Update: 20260903T235745+0000

Ratings and Alerts

No rating or validation information has been found for sigma-tau.

No alerts have been found for sigma-tau.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Barral L, et al. (2026) Targeting BMP and TAZ/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance. *Leukemia*, 40(6), 1151.

Pan CH, et al. (2026) Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. *Cancer research*, 86(12), 2935.

Sun M, et al. (2026) ER-derived caveolin-coated vesicles transport newly synthesized cholesterol to the plasma membrane. *The Journal of cell biology*, 225(6).

Rahmani M, et al. (2026) Type 2 diabetes disrupts T-tubule and RyR2 organization in male but not in female rat ventricular muscle. *American journal of physiology. Heart and circulatory physiology*, 330(4), H1048.

Jeon YH, et al. (2026) Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non-Small Cell Lung Cancer. *Cancer research communications*, 6(4), 913.

Xiao L, et al. (2025) An antibody targeting an immune checkpoint molecule BTN2A2 enhances anti-tumor immunity. *Neoplasia (New York, N.Y.)*, 65, 101161.

Wang Y, et al. (2025) Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. *Cancer research*, 85(11), 1997.

Bayet M, et al. (2025) Modeling the PAX5P80R Mutation Reveals HIF2? Activation as a Common Feature and Therapeutic Target in B-cell Acute Lymphoblastic Leukemia. *Cancer research*, 85(15), 2820.

Martínez-Quintanilla J, et al. (2024) Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4082.

Patkar S, et al. (2024) Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(24), 5630.

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. *Cancer research communications*, 4(6), 1441.